P 569

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584972

CAS#: 136880-97-2

Description: P 569 is an MRI contrast medium.


Price and Availability

Size
Price

Size
Price

Size
Price

P 569 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 584972
Name: P 569
CAS#: 136880-97-2
Chemical Formula: C17H22I3N3O9
Exact Mass: 792.849
Molecular Weight: 793.0884
Elemental Analysis: C, 25.75; H, 2.80; I, 48.00; N, 5.30; O, 18.16


Synonym: P 569; P569; P-569

IUPAC/Chemical Name: 1,3-Benzenedicarboxamide, 5-((2,3-dihydroxy-1-oxopropyl)(2,3-dihydroxypropyl)amino)-N-(2-hydroxyethyl)-N'-(hydroxymethyl)-2,4,6-triiodo-

InChi Key: JYGODJAOUUSBPH-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H22I3N3O9/c18-11-9(15(30)21-1-2-24)12(19)14(13(20)10(11)16(31)22-6-27)23(3-7(28)4-25)17(32)8(29)5-26/h7-8,24-29H,1-6H2,(H,21,30)(H,22,31)

SMILES Code: O=C(C1=C(I)C(N(C(C(O)CO)=O)CC(O)CO)=C(I)C(C(NCO)=O)=C1I)NCCO


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.90.01


References

1: Dai Y, Li C, Zhang F, Yang J, Chang S, Lu H, Yang H, Huang Z, Qian J, Ge L, Ge J. Safety and Efficacy of Percutaneous Coronary Intervention via Transradial Versus Transfemoral Approach in Bypass Grafts. Angiology. 2018 Feb;69(2):136-142. doi: 10.1177/0003319717711765. Epub 2017 Jun 12. PubMed PMID: 28602142.

2: Violon D. Analysis of the factors influencing the osmolality of eight monomeric nonionic iodinated contrast medium molecules. Invest Radiol. 1997 Nov;32(11):684-9. PubMed PMID: 9387056.

3: Zelichowska B, Rekas M, Stankiewicz A, Cerviño A, Montés-Micó R. Apodized diffractive versus refractive multifocal intraocular lenses: optical and visual evaluation. J Cataract Refract Surg. 2008 Dec;34(12):2036-42. doi: 10.1016/j.jcrs.2008.06.045. PubMed PMID: 19027556.

4: Li K, Miller C, Hegde S, Wojchowski D. Roles for an Epo receptor Tyr-343 Stat5 pathway in proliferative co-signaling with kit. J Biol Chem. 2003 Oct 17;278(42):40702-9. Epub 2003 Aug 9. PubMed PMID: 12909618.

5: Bonnemain B, Meyer D, Schaefer M, Dugast-Zrihen M, Legreneur S, Doucet D. New iodinated, low-osmolar contrast media. A revised concept of hydrophilicity. Invest Radiol. 1990 Sep;25 Suppl 1:S104-6. PubMed PMID: 2283218.